Mucosal adjuvants for influenza virus-like particle vaccine

Viral Immunology

Volumn 26, Issue 6, 2013, Pages 385-395

  Quan, Fu Shi ^a   Ko, Eun Ju ^b   Kwon, Young Man ^b   Joo, Kyoung Hwan ^c   Compans, Richard W ^d   Kang, Sang Moo ^b  

^a Kyung Hee University Hospital   (South Korea)

^b GEORGIA STATE UNIVERSITY   (United States)

^c Korea University College of Medicine   (South Korea)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; PHOSPHORYL LIPID A; POLYINOSINIC POLYCYTIDYLIC ACID; TUMOR NECROSIS FACTOR ALPHA; VIRUS LIKE PARTICLE VACCINE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LUNG; MDCK CELL; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PROVOCATION TEST; SPLEEN; SPLEEN CELL; SPLEEN LYMPHOCYTE; SURVIVAL RATE; VIRAL CLEARANCE; VIRUS LOAD; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, MUCOSAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-PRODUCING CELLS; BONE MARROW; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; SERUM; SPLEEN; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84890477528     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2013.0013     Document Type: Article

References (39)

1. Brewer JM, Conacher M, Satoskar A, Bluethmann H, and Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996;26: 2062-2066.
2. Bright RA, Carter DM, Daniluk S, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007;25:3871-3878.
3. Cheong HJ, Song JY, Heo JY. et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clin Vaccine Immunol 2011;18:1358-1364.
4. del Pilar Martin M, Weldon WC, Zarnitsyn VG, et al. Local response to microneedle-based influenza immunization in the skin. MBio 2012;3:e00012.
5. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS and Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008;453:1122-1126.
6. Frenck RW, Jr, Belshe R, Brady RC, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011;29:5666-5674.
7. Galarza JM, Latham T,and Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005;18: 244-251.
8. Garcon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, and Van Mechelen M. Development of an AS04- adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs 2011;25:217-226.
9. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24:5937-5949.
10. Haynes JR, Dokken L, Wiley JA, et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 2009;27:530-541.
11. Kang JH, Oh CE, Lee J, et al. Safety and immunogenicity of a new trivalent inactivated split-virus influenza vaccine in healthy Korean children: A randomized, double-blinded, active-controlled, phase III study. J Korean Med Sci 2011;26: 1421-1427.
12. Kang SM, Song JM, Quan FS, and Compans RW. Influenza vaccines based on virus-like particles. Virus Res 2009;143:140- 146.
13. Khatun S, Akram Hussain SM, Chowdhury S, et al. Safety and immunogenicity profile of human papillomavirus-16/ 18 AS04 adjuvant cervical cancer vaccine: A randomized controlled trial in healthy adolescent girls of Bangladesh. Jpn J Clin Oncol 2012;42:36-41.
14. Kim MC, Song JM, Kwon EOYM, Lee YJ, Compans RW, and Kang SM. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 2013;21:485-492.
15. Kim YC, Park JH, and Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 2012;64:1547-1568.
16. Kool M, Petrilli V, De Smedt T, et al. Cutting Edge: Alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008;181:3755-3759.
17. Kool M, Soullie T, van Nimwegen M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008;205: 869-882.
18. Koutsonanos DG, Vassilieva EV, Stavropoulou A, et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep 2012;2: 357.
19. Kwissa M., Amara RR, Robinson HL, et al. Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med 2007;204:2733-2746.
20. Martin M, Michalek SM, and Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003;71:2498-2507.
21. McKeage K, and Romanowski B. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix(R)): A review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 2011;71: 465-488.
22. Okamoto S, Matsuoka S, Takenaka N, et al. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clin Vaccine Immunol 2012;19:979-990.
23. Persing DH, Coler RN, Lacy MJ, et al. Taking toll: Lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 2002;10:S32-37.
24. Plotkin SA. Vaccines: Past, present and future. Nat Med 2005;11: S5-11.
25. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 2004;199:227-250.
26. Pulendran B, and Ahmed R. Translating innate immunity into immunological memory: Implications for vaccine development. Cell 2006;124:849-863.
27. Pulendran B, Lingappa J, Kennedy MK, et al. Developmental pathways of dendritic cells in vivo: Distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand- treated mice. J Immunol 1997;159:2222- 2231.
28. Quan FS, Compans RW, Nguyen HH, and Kang SM. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 2008;82:1350-1359.
29. Quan FS, Kim MC, Lee BJ, Song JM, Compans RW, and Kang SM. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology 2012;430:127- 135.
30. Quan FS, Steinhauer D, Huang C, Ross TM, Compans RW, and Kang SM. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 2008;26:3352-3361.
31. Quan FS, Vunnava A, Compans RW, and Kang SM. Viruslike particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One 2010;5:e9161.
32. Quan FS, Yoo DG, Song JM, Clements JD, Compans RW, and Kang SM. Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol 2009;83: 4489-4497.
33. Ragone G, Bresin A, Piermarini F, et al. The Tcl1 oncogene defines secondary hair germ cells differentiation at catagentelogen transition and affects stem-cell marker CD34 expression. Oncogene 2009;28:1329-1338.
34. Ross TM, Mahmood K, Crevar CJ, Schneider-Ohrum K, Heaton PM, and Bright RA. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One 2009;4:e6032.
35. Skountzou I, Martin MD, Wang B, et al. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 2010;28:4103- 4112.
36. Visciano ML, Tagliamonte M, Tornesello ML, Buonaguro FM, and Buonaguro L. Effects of adjuvants on IgG subclasses elicited by virus-like particles. J Transl Med 2012;10:4.
37. Wang BZ, Xu R, Quan FS, Kang SM, Wang L, and Compans RW. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One 2010; 5:e13972.
38. Wang XY, Yao X, Wan YM, Wang B, Xu JQ, and Wen YM. Responses to multiple injections with alum alone compared to injections with alum adsorbed to proteins in mice. Immunol Lett 2013;149:88-92.
39. Weldon WC, Zarnitsyn VG, Esser ES, et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS One 2012; 7:e41501.